Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Lymphangioleiomyomatosis Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Vendors: Novartis, Pfizer, AstraZeneca - Research and Markets

Research and Markets
Posted on: 07 Nov 16

Research and Markets has announced the addition of the "Lymphangioleiomyomatosis Global Clinical Trials Review, H2, 2016" clinical trials to their offering.

The clinical trial report, Lymphangioleiomyomatosis Global Clinical Trials Review, H2, 2016 provides an overview of Lymphangioleiomyomatosis clinical trials scenario. This report provides top line data relating to the clinical trials on Lymphangioleiomyomatosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database.


  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

Reasons to buy:

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned:

  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca Plc
  • Tuberous Sclerosis Alliance
  • Nobelpharma Co., Ltd.
  • MultiMedica S.p.A.
  • LAM Therapeutics
  • C. H. Boehringer Sohn AG & Co. KG

For more information about this clinical trials report visit

View source version on

Business Wire

Last updated on: 07/11/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.